Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.35 |
| ▸ | MME | P08473 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | DNMT1 | P26358 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2128258 | 0.76 | ALDH1A1 (0.49) | ALDH1A1PKMSLC1A2MMEKMT2A | |
| SCHEMBL987319 | 0.72 | MAPK1 (0.52) | ALDH1A1PKMMMEKMT2A | |
| SCHEMBL988202 | 0.72 | MAPK1 (0.52) | ALDH1A1PKMMMEKMT2A | |
| SCHEMBL698898 | 0.72 | ALDH1A1 (0.56) | ALDH1A1PKMSLC1A2MMEKMT2A | |
| SCHEMBL10421278 | 0.71 | ALDH1A1 (0.54) | ALDH1A1PKMSLC1A2MMEKMT2A | |
| SCHEMBL73144 | 0.71 | ALDH1A1 (0.54) | ALDH1A1PKMSLC1A2MMEKMT2A | |
| SCHEMBL3505155 | 0.70 | ALDH1A1 (0.58) | ALDH1A1PKMSLC1A2MMEKMT2A | |
| SCHEMBL12100863 | 0.69 | ALDH1A1 (0.53) | ALDH1A1PKMSLC1A2MMEKMT2A | |
| SCHEMBL15623808 | 0.69 | ALDH1A1 (0.53) | ALDH1A1PKMSLC1A2MME | |
| SCHEMBL1269476 | 0.69 | ALDH1A1 (0.53) | ALDH1A1PKMSLC1A2MMEKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2379501-B1 | METHOD FOR PREPARING ACTIVATED ESTERS | SANOFI SA (FR) | 2014-01-22 | — | — | EP | disclosed |
| US-8314244-B2 | Method for preparing activated esters | SANOFI (FR) | 2012-11-20 | — | — | US | disclosed |
| US-20110313168-A1 | METHOD FOR PREPARING ACTIVATED ESTERS | SANOFI (FR) | 2011-12-22 | — | — | US | disclosed |
| EP-2379501-A1 | METHOD FOR PREPARING ACTIVATED ESTERS | SANOFI (FR) | 2011-10-26 | — | — | EP | disclosed |
| WO-2010076474-A1 | METHOD FOR PREPARING ACTIVATED ESTERS | SANOFI-AVENTIS (FR) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110313168-A1 | METHOD FOR PREPARING ACTIVATED ESTERS | C9, C1S, ALK | ALDH1A1 1913/4885PKM 2399/4885SLC1A2 2222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.